Xingrui Chen, Minting Ye, Ruyu Ai, Changguo Shan, Minyao Lai, Weiping Hong, Yanying Yang, Hui Wang, Juan Li, Junjie Zhen, Jiangfen Zhou, Qingjun Hu, Shaoqun Li, Antonio Rossi, Toyoaki Hida, Rafael Rosell, Shuisheng Zhong, Linbo Cai
BACKGROUND: Immune-related adverse effects (irAEs) often occur during immune checkpoint inhibitor (ICI) therapy. In the nervous system, the incidence of irAEs ranges from 0.1-12%, with 80% occurring within the first 4 months of ICI application. For complications of the nervous system, adequate diagnosis is made by signs, symptoms, imaging and cerebrospinal fluid. If severe irAEs occur, ICIs should be discontinued and patients should be treated with high-dose glucocorticoids, immunoglobulins, or immunosorbent therapy with systemic support...
February 29, 2024: Translational Cancer Research